All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-PD-L1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human PD-L1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PD-L1 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of B-cell malignancies.
CAR Construction : MEDI4736 scFv-BBζ Fig.1 Flow cytometry data showing that PD-L1 is expressed on the surface of almost all PDL1-K562 cells. Generation and validation of PDL1-K562 cells. Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021). APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY), 13(5), 7199. |
CAR Construction : MEDI4736 scFv-BBζ Fig.2 Transmitted light and fluorescence microscopy images of aPDL1-K562 cells in co-culture with PDL1-K562 cells or K562 cells for 4 h (200×). Green labeling corresponds to aPDL1-K562 cells, and red labeling indicates PDL1-K562 and K562 cells. Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021). APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY), 13(5), 7199. |
CAR Construction : MEDI4736 scFv-BBζ Fig.3 Identification of aPDL1-CART cells by flow cytometry analysis of EGFP fluorescence. Non-transduced T cells served as control. Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021). APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY), 13(5), 7199. |
CAR Construction : MEDI4736 scFv-BBζ Fig.4 Cytotoxicity and cytokine secretion analyses on aPDL1-CART cells in vitro. The cytotoxic activity of effectors was evaluated by flow cytometry based on distinct labeling of target cells (mCherry+) and aPDL1-CART cells (EGFP+) following co-culture with PDL1-CA46 cells. Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021). APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY), 13(5), 7199. |
CAR Construction : MEDI4736 scFv-BBζ Fig.5 ELISA measurements of IL-2 and IFN-γ secretion in control T cells (red) and aPDL1-CART cells. * P < 0.05. Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021). APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY), 13(5), 7199. |
CAR Construction : MEDI4736 scFv-BBζ Fig.6 Transmitted light and fluorescence microscopy imaging of aPDL1-CART cells co-cultured with leukemia cells for 24 h (200×). n = 3 per group. Peng, Q., Zhu, X., Li, C., Xin, P., Zheng, Y., & Liu, S. (2021). APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. Aging (Albany NY), 13(5), 7199. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PD-L1 (MEDI4736) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP258). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION